NCT03146468

Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation

Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (estimated)
• Sponsor: Melbourne Health · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective study of the safety and efficacy of nivolumab for the treatment of relapsed or residual haematological malignancies after allogeneic stem cell transplantation (alloSCT). Eligible patients will receive nivolumab at a dose of 3mg/kg intravenously every 2 weeks. The primary objective is to evaluate the incidence, severity and treatment responsiveness of GVHD following nivolumab treatment post-alloSCT.

Conditions

• Haematological Malignancy

Interventions

Type	Name	Description
DRUG	Nivolumab Injection	Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor

Timeline

• Start date: 2017-05-08
• Primary completion: 2022-03-01
• Completion: 2022-03-01
• First posted: 2017-05-10
• Last updated: 2021-09-23

Locations

1 site across 1 country: Australia

Regulatory

• FDA-regulated drug study